We are live on ! Find out more
ATXI

Avenue Therapeutics, Inc. Common Stock

Delisted

ATXI was delisted on the 18th of March, 2025.

17 hedge funds and large institutions have $1.62M invested in Avenue Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

29% less funds holding

Funds holding: 2417 (-7)

44% less capital invested

Capital invested by funds: $2.88M → $1.62M (-$1.26M)

64% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 11

Holders
17
Holders Change
-7
Holders Change %
-29.17%
% of All Funds
0.3%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
5
Reduced
4
Closed
11
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
PPA
26
Parametric Portfolio Associates
Washington
-$26K -9 Closed
Bank of America
27
Bank of America
North Carolina
-$4.13K -2 Closed
JP Morgan Chase
28
JP Morgan Chase
New York
-$2K -1 Closed
Royal Bank of Canada
29
Royal Bank of Canada
Ontario, Canada
-$2.07K -1 Closed

ATXI Hedge Fund Activity: Q3 2021 in Review

17 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q3 2021, worth a combined $1.62M — down 44% from $2.88M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of ATXI and 4 opened new positions — a net loss of 7 holders — while 4 trimmed existing stakes and 5 added.

The largest buyer was Wells Fargo, opening a new position worth an estimated $88.9K. The largest seller was Advisory Services Network, exiting entirely with an estimated $88K sold.

  • 17 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q3 2021, down from 24 in Q2 2021.
  • Funds reported $1.62M of Avenue Therapeutics, Inc. Common Stock stock for Q3 2021, down 44% quarter-over-quarter.
  • 4 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q3 2021 and 11 closed out, a net change of -7 holders.
  • The largest Avenue Therapeutics, Inc. Common Stock buyer in Q3 2021 was Wells Fargo, an estimated $88.9K added.
  • The largest Avenue Therapeutics, Inc. Common Stock seller in Q3 2021 was Advisory Services Network, an estimated $88K sold.

Based on aggregated 13F filings for Q3 2021.